Tag Archive for: commercialisation

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

/in

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region The transaction significantly strengthens Hansa’s financial position and enables a robust US launch, subject to US approval of imlifidase Lund, Sweden, July 1, 2026. Hansa Biopharma AB (“Hansa” or “the Company”) (Nasdaq Stockholm: HNSA) and […]

Read more
xeltis

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization

/in

CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule to commercialization aXess™ reduces the need for vascular access interventions enabling more streamlined kidney care delivery EINDHOVEN, The Netherlands – 21 April, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation […]

Read more

Hansa Biopharma publishes 2025 Annual and Sustainability Reports

/in

Lund, Sweden, 26 March 2026. Hansa Biopharma AB, “Hansa” or the “Company” (Nasdaq Stockholm: HNSA), today published its Annual and Sustainability Reports for 2025. Peter Nicklin, Chair of the Board, Hansa Biopharma, said: “2025 was a year of transformation for Hansa Biopharma, marked by the appointment of Renée Aguiar‑Lucander as our new CEO with a clear […]

Read more

Futura Medical Interim Results for the Six Months ended 30 June 2022

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce its unaudited interim results for the six months ended 30 June 2022. Read more…

Read more
© Optimum Strategic Communications.